Replies to post #291420 on Bioelectronics Corp (BIEL)

[Threepointer]

“The thing is, it didn't mean that the SEC investigations were faulty, or wrong, or anything that folks like to claim. It just meant that the process used to hire the judges was no longer seen as acceptable.”

Lmfao, and it didn’t mean the investigations were NOT faulty or correct either. Jesus, it had NOTHING TO DO THE PROCESS USED TO HIRE JUDGES. It had to do with how they were ruling. Hilarious interpretation. Like it or not.

[srinsocal]

This is a NEW Ruling Against the SEC not the SCOTUS Ruling of 3 years ago

That's right the SEC disregarded another Law to make it easier for them to obtain a conviction.

The SCOTUS Ruling of 3 years ago was for the SEC's Judge hiring policies violating the Constitution.

This new ruling is from the 5th U.S. Circuit Court of Appeals dated 5/18/2022 and involves the SEC not giving Defendents the option of a Trial by Jury.

SEC in-house judges violate the right to a jury trial, appeals court rules
PUBLISHED WED, MAY 18 20225:47 PM EDTUPDATED WED, MAY 18 20225:48 PM EDT

The Securities and Exchange Commission’s in-house judges violate the U.S. Constitution by denying fraud defendants their right to a jury trial and acting without necessary guidance from Congress, the 5th U.S. Circuit Court of Appeals ruled on Wednesday.

The court ruled 2-1 in favor of hedge fund manager George Jarkesy Jr and investment advisor Patriot28 LLC, overturning an SEC administrative law judge’s determination that they committed securities fraud.

A spokesperson for the SEC and counsel for the petitioners did not immediately respond to a request for comment on Wednesday.

The Dodd-Frank Act, which Congress passed after the 2008 financial crisis, expanded the SEC’s ability to seek penalties in its administrative proceedings.

In the ruling Wednesday, the majority said that because seeking penalties is akin to debt collection, which is a private right, the defendants were entitled to a jury trial.

https://www.cnbc.com/2022/05/18/sec-in-house-judges-violate-right-to-jury-trial-appeals-court-rules.html

[edbi46]

Viva La Andy !!
Viva La KELLY !!
Viva La KEITH !!
Viva La SREE !!
Viva La RICHARD !!
BIEL$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
BioElectronics Corp. (OTCPINK: $BIEL) Powerful Reversal Brewing as Pain Management Pioneer Launches RecoveryRx into Mexico & Spain

Quote:
BioElectronics Corp. (OTCPINK: BIEL) recently hit lows of $0.0005 and accumulation has begun in earnest in recent days in red overall markets. Microcapdaily has been reporting on BIEL for years and covered them in triple digits back in November shortly after the Company received CE (Conformité Européenne) Mark for its ActiPatch® and RecoveryRx®. These wearable devices can now be sold over the counter in 33 European Union (EU) countries, and many other non-EU countries like Australia that recognize the CE mark. This comes shortly after the Company acquired three 510(k) clearances from the U.S. Food & Drug Administration (FDA). Biotech’s are among the most explosive stocks in penny stocks and BIEL has a significant gap to fill from $0.038 highs of February 2021. The stock has a large investor following that will buy in significantly as soon as BIEL makes a significant reversal.

BIEL has been busy since executing the OEM agreement with KT Health in December; the Company is now working with their three major channel partners, i.e., KT Health and Scott Specialties in the OTC space, and Medi-Launch in the prescription medical market, to solidify new orders after strong initial product launches that took place in Q1 2021. The Company is also pushing forward on the international sales front. In addition to re-acquiring their CE mark (which allows the Company to sell in most international countries) in late 2020, it also obtained MDSAP certification in Q1 2021, which now allows for product distribution in Canada, Australia, and New Zealand. More recently BIEL’s distribution partner in Mexico received authorization from Mexican FDA (Cofepris), which allows for the importation of the RecoveryRx® device into Mexico. Novro Med S.A. de C.V. has contracted for the exclusive distribution rights for RecoveryRx® in Mexico and it is expected that they will receive their initial stocking order during the 2nd quarter, 2022. The Company also entered into a distribution agreement with Madrid / Spain based PRIM Group for the distribution of its RecoveryRx device throughout Spain. As per latest filings BIEL is topping well over $100,000 a month in sales.


https://microcapdaily.com/bioelectronics-corp...ico-spain/

https://www.bielcorp.com/bioelectronics-corporation-reports-double-digit-quarterly-sales-growth-kt-health-and-djo-launches-outpacing-forecasts/


https://www.prnewswire.com/news-releases/kt-tape-launches-kt-recovery-wave-301232376.html

https://www.bielcorp.com/bioelectronics-corporation-announces-substantial-increase-in-4th-quarter-2020-revenue-major-convertible-debt-holders-agree-to-forego-interest-in-2021/

https://www.bielcorp.com/bioelectronics-actipatch-therapy-to-be-marketed-by-donjoy-advantage/

https://www.bielcorp.com/bioelectronics-announces-fda-market-clearance-for-over-the-counter-treatment-of-musculoskeletal-pain/